Scientific Advisory Board

Scientific Advisory Board

The Scientific Advisory Board lends their knowledge and expertise in the pursuit of innovation.
Richard Honkanen, PhD
Inventor
Richard Honkanen is the inventor of the original technology on which Repair Biotechnologies’ CDP platform is based. He is a Professor in the Department…
Read bio
Graham Pawelec, PhD
Immunology
Graham Pawelec is an advisor to Repair Biotechnologies, with deep expertise in immunology and oncology. He is currently Professor of Experimental…
Read bio
Andrew Zhu, MD, PhD
Oncology

Dr. Andrew X. Zhu is Director of Jiahui International Cancer Center, Director Emeritus of Liver Cancer Research at Massachusetts General Hospital Cancer Center, and Professor of Medicine at Harvard Medical School…

Read bio
About
Navigate
Contact
Repair Biotechnologies, Inc.
841 East Fayette St
Syracuse, NY 13210
Linkedin
Linkedin
  • © 2024 Repair Bio. All Rights Reserved.

Richard Honkanen, PhD

Inventor
Richard Honkanen is the inventor of the original technology on which Repair Biotechnologies’ CDP platform is based. He is a Professor in the Department of Biochemistry & Molecular Biology in the College of Medicine, University of South Alabama. Dr. Honkanen’s lab has been a pioneer in the study of atherosclerosis and other age-related diseases, having published extensively on cholesterol catabolism, the molecular mechanisms of carcinogenesis, and mechanisms of cardioprotective agents in ischemic myocytes. He has a PhD in Microbiology from the University of Georgia.

Graham Pawelec, PhD

Immunology
Graham Pawelec is an advisor to Repair Biotechnologies, with deep expertise in immunology and oncology. He is currently Professor of Experimental Immunology in the Department of Immunology, University of Tübingen, Tübingen, Germany and is a member of the Cancer Solutions Program at the Health Sciences North Research Institute of Canada, Sudbury, ON, Canada. Dr. Pawelec is Co-Editor-in Chief of “Immunity and Ageing”. His research interests center on alterations to immunity, especially T cell-mediated immunity, in aging and cancer in man, and the influence these have on the outcome of vaccination and immunomodulatory antibody therapies, inflammatory and neurodegenerative disease, and autoimmunity. He has an MA in Natural Sciences and a PhD in Transplantation Immunology from the University of Cambridge, UK.

Andrew Zhu, MD, PhD

Oncology

Dr. Andrew X. Zhu is Director of Jiahui International Cancer Center, Director Emeritus of Liver Cancer Research at Massachusetts General Hospital Cancer Center, and Professor of Medicine at Harvard Medical School.
The major focus of his research is to develop more effective therapies for hepatocellular carcinoma (HCC), cholangiocarcinoma, and other gastrointestinal cancers.

Dr. Zhu has served as a principal investigator in many clinical trials in HCC and cholangiocarcinoma. An internationally recognized authority in HCC and cholangiocarcinoma, he led early efforts and pivotal studies of developing several molecularly targeted, immunotherapeutic agents, and combination regimens in liver cancers that received regulatory approval.

He is a founding member of the International Liver Cancer Association, a Fellow at the American College of Physicians, and a member of ASCO and AACR. Dr. Zhu has served on the Hepatobiliary Cancer committee of the National Comprehensive Cancer Network, the Grants Selection Committee of ASCO, the Hepatobiliary Cancer Task Force of The NCI Gastrointestinal Cancer Steering Committee, the American Joint Committee on Hepatobiliary Cancer Task Force, the Hepatocellular Carcinoma Practice Guidelines Committee of the American Association for the Study of Liver Diseases, and the Clinical Advisory Board of The Cholangiocarcinoma Foundation. He has received several awards for his work, including V Foundation Translational Research Award, Lorenzo Cappussotti Award, and Jonathan Kraft Translational Award.